Press Releases 2012˜

Amorfix Announces The Development Of Antibodies That Bind to Misfolded Fas Receptor Protein As A Potential Treatment For Cancer

May 16, 2012

Amorfix has developed antibodies that selectively target and bind to misfolded Fas receptor protein expressed on the cell surface of cancer cells.

Download PDF

Amorfix Closes Private Placement Offering

May 14, 2012

Amorfix has closed a non-brokered private placement (the Offering) pursuant to which a total of 2,585,000 units (Units) were issued at a price of $0.40 per unit for gross proceeds of $1,034,000.

Download PDF

Amorfix Announces Private Placement

May 08, 2012

Amorfix intends to complete, subject to regulatory approval, a non-brokered private placement of up to 2,500,000 units (Units) at a price of $0.40 per Unit, for gross proceeds of $1,000,000, of which commitments to subscribe for 2,200,000 units have been received.

Download PDF

Amorfix To Collaborate With World Leader In Prion Diagnostic Research

May 1, 2012

Amorfix has established a collaboration with Dr. Detlev Riesner, a world leader in prion diagnostics, using Amorfix’s proprietary prion antibody in a promising new blood test for animal prion infection.

Download PDF

Amorfix Chief Scientific Officer Receives Genome BC Award For Scientific Excellence

April 17, 2012

Amorfix announces that its CSO, Director and Company founder, Dr. Neil Cashman, has been awarded the 2012 Genome BC Award for Scientific Excellence. This award is presented annually by Genome BC to recognize individuals who have made outstanding contributions to the development of British Columbia’s life sciences industry across all sectors which are critical to the economic future of the province and country.

Download PDF

Amorfix Establishes Proof of Concept Of Lead Tumor-Specific Antibody For The Treatment Of Ovarian Cancer

April 4, 2012

Amorfix has completed a series of studies with its lead anti-PrP antibody that demonstrate specific, dose-related killing of ovarian tumor cells.

Download PDF

Amorfix Acquires SOD1 Technology and Provides Update on Financing

March 12, 2012

Amorfix acquires the SOD1 technology and closes second and final tranche of a previously announced non brokered private placement.

Download PDF

Amorfix to Present at BioPartnering North America

February 27, 2012

Amorfix announces that CEO Dr. Robert Gundel will present a corporate overview at the BioPartnering meeting on February 28, 2012 in Vancouver, BC.

Download PDF

Amorfix Appoints Lynda Covello Vice President of Strategic Alliances

February 23, 2012

Amorfix has appointed Lynda Covello as Vice President of Strategic Alliances.

Download PDF

Amorfix Announces Third Quarter Fiscal 2012 Results

February 10, 2012

Amorfix announced its operational and financial results for the third quarter ended December 31, 2011.

Download PDF

Amorfix To Participate In Canadian Neuroscience Partnering Trade Mission To Europe

January 23, 2012

Amorfix Life has agreed to participate in a neuroscience partnering trade mission to Europe organized by the Department of Foreign Affairs and International Trade.

Download PDF

Amorfix Closes First Tranche Of Private Placement

January 18, 2012

Amorfix has closed the first tranche of a non-brokered private placement (the Offering) pursuant to which a total of 3,012,532 units (Units) were issued at a price of $0.225 per unit for gross proceeds of $677,820.

Download PDF

Amorfix and JSW Sign LOI For Exclusive Worldwide License of Preclinical Alzheimer's Disease Diagnostic Technology

January 9, 2012

Amorfix has signed a letter of intent with JSW-Lifesciences GmbH, a contract research organization specializing in Alzheimer's and other CNS diseases, to license its pre-clinical Alzheimer's disease diagnostic test, the Amorfix Aggregated Abeta Assay (the A4).  JSW plans to add the A4 to its suite of preclinical research services provided to pharmaceutical companies and academic research institutions involved in Alzheimer's disease research and development.

Download PDF